Triage Administration of Ondansetron for Gastroenteritis in Children
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03052361|
Recruitment Status : Terminated (The recruitment was much slower than expected and the COVID pandemic added new barriers to recruitment.)
First Posted : February 14, 2017
Last Update Posted : October 22, 2020
|Condition or disease||Intervention/treatment||Phase|
|Gastroenteritis||Drug: Ondansetron Drug: Placebos||Phase 2 Phase 3|
Acute gastroenteritis is one the most common cause of emergency room visits. Studies have demonstrated that ondansetron is effective in reducing vomiting in children with gastroenteritis and improve outcomes by decreasing intravenous rehydration and hospital admission of those patients. Giving ondansetron to children with suspected gastroenteritis immediately at triage could reduce the number of patients requiring observation in the emergency department after medical consultation and improve patients' outcomes.
The aim of this study is to assess the effectiveness of triage-initiated administration of ondansetron for suspected gastroenteritis in the paediatric emergency department. The investigators aim to assess whether ondansetron given at triage can reduce the number of patients requiring observation in children with acute gastroenteritis. The investigators will also assess the improvement of patient comfort and total length of stay.
This will be a randomized controlled trial performed in a tertiary paediatric emergency department. Participants will include all infants more than 8kg who present to the emergency department with at least four vomiting in the previous 24 hours and the last vomiting that occurred in the previous 2h. The intervention will consist of giving ondansetron at triage versus placebo. The primary outcome will be the number of patients requiring observation after medical consultation in both groups. Secondary objectives will be the number of episodes of vomiting after receiving the intervention, length of stay in the emergency department and the proportion of children who will return to a physician within 48 hours. The investigators will assess the improvement of patient comfort evaluated by parents according to a BARF (Baxter Animated Retching Face) Scale within the ondansetron group vs placebo. The primary analysis will be the comparison of the proportion of observation for the two groups. Based on a preliminary study of the currents children suffering from gastro-enteritis, it was estimated that the recruitment of 248 participants will provide a power of 90% to identify a 20% difference in the proportion of observed patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||81 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Triage Administration of Ondansetron for Gastroenteritis in Children; a Randomized Controlled Trial|
|Actual Study Start Date :||July 15, 2017|
|Actual Primary Completion Date :||September 3, 2020|
|Actual Study Completion Date :||October 3, 2020|
Patients allocated to this arm will receive ondansetron in the ED triage. Posology of ondansetron will be adapted to weight: doses of 2 mg for children weighting between 8 and 15 kg, 4 mg for children weighting between 15 to 30 kg and 8 mg for children heavier than 30 kg
Patients allocated to this arm will receive ondansetron in the ED triage.
Other Name: Zofran
Placebo Comparator: control
Patients allocated to this arm will receive an identical looking/tasting placebo in the ED triage.
similar looking and tasting liquid placebo
- Disposition [ Time Frame: 12 hours ]The number of patients that are discharged immediately after initial medical assessment
- Length of Stay [ Time Frame: 12 hours ]The ED length of stay from registration to discharged
- ED vomiting [ Time Frame: 12 hours ]The number of episodes of vomiting in the ED.
- 48 hours vomiting [ Time Frame: 48 hours ]The number of episodes of vomiting in the 24 and 48 hours
- Return visit [ Time Frame: 48 hours ]The number of patients who return to ED and to a physician within 48 hours.
- Nausea level [ Time Frame: 12 hours ]Improvement of patient comfort evaluated by parents according to a Baxter Animated Retching Face Scale (BARF) scale
- Alternative diagnosis [ Time Frame: 12 hours ]In a safety analysis, the investigator will evaluate if the nurse at triage was correct in suspecting that the enrolled children were suffering from gastroenteritis and we will compare the proportion of alternate diagnosis in both groups
- Left without being sen [ Time Frame: 12 hours ]The investigator will compare the proportion of children who left the ED without being seen by a physician.
- Rescue medication [ Time Frame: 12 hours ]The proportion of children requiring a rescue medication for persistent nausea/vomiting
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03052361
|Montreal, Quebec, Canada, H3T1C5|
|Principal Investigator:||Jocelyn Gravel, MD||Sainte-Justine Hospital|